Multiple sclerosis-associated uveitis

References

• McDonald WI, Compston A, Edan G et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann. Neurol. 50(1), 121–127 (2001).
   PubMed Web of Science ®Google Scholar
• Polman CH, Reingold SC, Banwell B et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann. Neurol. 69(2), 292–302 (2011).
   PubMed Web of Science ®Google Scholar
• Graves J, Balcer LJ. Eye disorders in patients with multiple sclerosis: natural history and management. Clin. Ophthalmol. 4, 1409–1422 (2010).
   PubMedGoogle Scholar
• Chen L, Gordon LK. Ocular manifestations of multiple sclerosis. Curr. Opin. Ophthalmol. 16(5), 315–320 (2005).
   PubMedGoogle Scholar
• Compston A, Coles A. Multiple sclerosis. Lancet 359(9313), 1221–1231 (2002).
   PubMed Web of Science ®Google Scholar
• Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 46(4), 907–911 (1996).
   PubMed Web of Science ®Google Scholar
• Rucker CW. Retinopathy of Multiple Sclerosis. Trans. Am. Ophthalmol. Soc. 45, 564–570 (1947).
   PubMedGoogle Scholar
• Jabs DA, Nussenblatt RB, Rosenbaum JT; Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am. J. Ophthalmol. 140(3), 509–516 (2005).
   PubMed Web of Science ®Google Scholar
• Bregerbc, Leopold IH. The incidence of uveitis in multiple sclerosis. Am. J. Ophthalmol. 62(3), 540–545 (1966).
   PubMed Web of Science ®Google Scholar
• Giles CL. Peripheral uveitis in patients with multiple sclerosis. Am. J. Ophthalmol. 70(1), 17–19 (1970).
   PubMed Web of Science ®Google Scholar
• Malinowski SM, Pulido JS, Folk JC. Long-term visual outcome and complications associated with pars planitis. Ophthalmology 100(6), 818–824; discussion 825 (1993).
   PubMed Web of Science ®Google Scholar
• Raja SC, Jabs DA, Dunn JP et al. Pars planitis: clinical features and class II HLA associations. Ophthalmology 106(3), 594–599 (1999).
   PubMed Web of Science ®Google Scholar
• Optic Neuritis Study Group. Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up. Arch. Neurol. 65(6), 727–732 (2008).
   PubMedGoogle Scholar
• The 5-year risk of MS after optic neuritis: experience of the optic neuritis treatment trial. 1997. Neurology 57(12 Suppl. 5), S36–45 (2001).
   PubMed Web of Science ®Google Scholar
• Beck RW, Cleary PA, Anderson MM Jr et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N. Engl. J. Med. 326(9), 581–588 (1992).
   PubMed Web of Science ®Google Scholar
• Smith JR, Rosenbaum JT. Neurological concomitants of uveitis. Br. J. Ophthalmol. 88(12), 1498–1499 (2004).
   PubMed Web of Science ®Google Scholar
• Bamford CR, Ganley JP, Sibley WA, Laguna JF. Uveitis, perivenous sheathing and multiple sclerosis. Neurology 28(9 Pt 2), 119–124 (1978).
   PubMed Web of Science ®Google Scholar
• Porter R. Uveitis in association with multiple sclerosis. Br. J. Ophthalmol. 56(6), 478–481 (1972).
   PubMed Web of Science ®Google Scholar
• Arnold AC, Pepose JS, Hepler RS, Foos RY. Retinal periphlebitis and retinitis in multiple sclerosis. I. Pathologic characteristics. Ophthalmology 91(3), 255–262 (1984).
   PubMed Web of Science ®Google Scholar
• Langer-Gould A, Albers KB, Van Den Eeden SK, Nelson LM. Autoimmune diseases prior to the diagnosis of multiple sclerosis: a population-based case–control study. Mult. Scler. 16(7), 855–861 (2010).
   PubMed Web of Science ®Google Scholar
• Biousse V, Trichet C, Bloch-Michel E, Roullet E. Multiple sclerosis associated with uveitis in two large clinic-based series. Neurology 52(1), 179–181 (1999).
   PubMed Web of Science ®Google Scholar
• James DG, Friedmann AI, Graham E. Uveitis. A series of 368 patients. Trans. Ophthalmol. Soc. U. K. 96(1), 108–112 (1976).
   PubMedGoogle Scholar
• Zein G, Berta A, Foster CS. Multiple sclerosis-associated uveitis. Ocul. Immunol. Inflamm. 12(2), 137–142 (2004).
   PubMed Web of Science ®Google Scholar
• Nathanson N, Miller A. Epidemiology of multiple sclerosis: critique of the evidence for a viral etiology. Am. J. Epidemiol. 107(6), 451–461 (1978).
   PubMed Web of Science ®Google Scholar
• Donaldson MJ, Pulido JS, Herman DC, Diehl N, Hodge D. Pars planitis: a 20-year study of incidence, clinical features, and outcomes. Am. J. Ophthalmol. 144(6), 812–817 (2007).
   PubMed Web of Science ®Google Scholar
• Prieto JF, Dios E, Gutierrez JM, Mayo A, Calonge M, Herreras JM. Pars planitis: epidemiology, treatment, and association with multiple sclerosis. Ocul. Immunol. Inflamm. 9(2), 93–102 (2001).
   PubMed Web of Science ®Google Scholar
• Rucker CW. Sheathing of the retinal veins in multiple sclerosis. Res. Publ. Assoc. Res. Nerv. Ment. Dis. 28, 396–402 (1950).
   PubMedGoogle Scholar
• Welch RB, Maumenee AE, Wahlen HE. Peripheral posterior segment inflammation, vitreous opacities, and edema of the posterior pole. Arch. Ophthalmol. 64, 540–549 (1960).
   PubMedGoogle Scholar
• Lightman S, McDonald WI, Bird AC et al. Retinal venous sheathing in optic neuritis. Its significance for the pathogenesis of multiple sclerosis. Brain 110(Pt 2), 405–414 (1987).
   PubMed Web of Science ®Google Scholar
• Kerrison JB, Flynn T, Green WR. Retinal pathologic changes in multiple sclerosis. Retina (Philadelphia) 14(5), 445–451 (1994).
   PubMed Web of Science ®Google Scholar
• Schmidt S, Wessels L, Augustin A, Klockgether T. Patients with Multiple Sclerosis and concomitant uveitis/periphlebitis retinae are not distinct from those without intraocular inflammation. J. Neurol. Sci. 187(1–2), 49–53 (2001).
   PubMed Web of Science ®Google Scholar
• Campbell JP, Leder HA, Sepah YJ et al. Wide-field retinal imaging in the management of noninfectious posterior uveitis. Am. J. Ophthalmol. 154(5), 908–911 (2012).
   PubMed Web of Science ®Google Scholar
• Sepulcre J, Murie-Fernandez M, Salinas-Alaman A, García-Layana A, Bejarano B, Villoslada P. Diagnostic accuracy of retinal abnormalities in predicting disease activity in MS. Neurology 68(18), 1488–1494 (2007).
   PubMed Web of Science ®Google Scholar
• Engell T. Neurological disease activity in multiple sclerosis patients with periphlebitis retinae. Acta Neurol. Scand. 73(2), 168–172 (1986).
   PubMed Web of Science ®Google Scholar
• Tola MR, Granieri E, Casetta I et al. Retinal periphlebitis in multiple sclerosis: a marker of disease activity? Eur. Neurol. 33(2), 93–96 (1993).
   PubMed Web of Science ®Google Scholar
• Towler HM, Lightman S. Symptomatic intraocular inflammation in multiple sclerosis. Clin. Experiment. Ophthalmol. 28(2), 97–102 (2000).
   PubMed Web of Science ®Google Scholar
• Le Scanff J, Sève P, Renoux C, Broussolle C, Confavreux C, Vukusic S. Uveitis associated with multiple sclerosis. Mult. Scler. 14(3), 415–417 (2008).
   PubMed Web of Science ®Google Scholar
• Engell T, Jensen OA, Klinken L. Periphlebitis retinae in multiple sclerosis. A histopathological study of two cases. Acta Ophthalmol. (Copenh). 63(1), 83–88 (1985).
   PubMedGoogle Scholar
• Schmidt S, Linington C, Zipp F et al. Multiple sclerosis: comparison of the human T-cell response to S100 β and myelin basic protein reveals parallels to rat experimental autoimmune panencephalitis. Brain 120(Pt 8), 1437–1445 (1997).
   PubMed Web of Science ®Google Scholar
• Kellar-Wood HF, Wood NW, Holmans P, Clayton D, Robertson N, Compston DA. Multiple sclerosis and the HLA-D region: linkage and association studies. J. Neuroimmunol. 58(2), 183–190 (1995).
   PubMed Web of Science ®Google Scholar
• Duquette P, Décary F, Pleines J et al. Clinical sub-groups of multiple sclerosis in relation to HLA:DR alleles as possible markers of disease progression. Can. J. Neurol. Sci. 12(2), 106–110 (1985).
   PubMed Web of Science ®Google Scholar
• Malinowski SM, Pulido JS, Goeken NE, Brown CK, Folk JC. The association of HLA-B8, B51, DR2, and multiple sclerosis in pars planitis. Ophthalmology 100(8), 1199–1205 (1993).
   PubMed Web of Science ®Google Scholar
• Voskuhl RR, Goldstein AM, Simonis T, Davey RJ, McFarland HF. DR2/DQw1 inheritance and haplotype sharing in affected siblings from multiple sclerosis families. Ann. Neurol. 39(6), 804–807 (1996).
   PubMed Web of Science ®Google Scholar
• Frederiksen JL, Madsen HO, Ryder LP, Larsson HB, Morling N, Svejgaard A. HLA typing in acute optic neuritis. Relation to multiple sclerosis and magnetic resonance imaging findings. Arch. Neurol. 54(1), 76–80 (1997).
   PubMedGoogle Scholar
• Tang WM, Pulido JS, Eckels DD, Han DP, Mieler WF, Pierce K. The association of HLA-DR15 and intermediate uveitis. Am. J. Ophthalmol. 123(1), 70–75 (1997).
   PubMed Web of Science ®Google Scholar
• Oruc S, Duffy BF, Mohanakumar T, Kaplan HJ. The association of HLA class II with pars planitis. Am. J. Ophthalmol. 131(5), 657–659 (2001).
   PubMed Web of Science ®Google Scholar
• Patte M, Rouher FN, Vernay D, Delaire JC, Bacin F. Proliferative retinal vasculitis and multiple sclerosis: a case report. J. Fr. Ophtalmol. 26(4), 381–385 (2003).
   PubMed Web of Science ®Google Scholar
• Ronzani M, Lang GE, Wagner P, Lang GK. Severe occlusive retinal periphlebitis with vitreous hemorrhage in multiple sclerosis. Ger. J. Ophthalmol. 4(6), 328–331 (1995).
   PubMedGoogle Scholar
• Bonfioli AA, Damico FM, Curi AL, Orefice F. Intermediate uveitis. Semin. Ophthalmol. 20(3), 147–154 (2005).
   PubMedGoogle Scholar
• Park SE, Mieler WF, Pulido JS. 2 peripheral scatter photocoagulation for neovascularization associated with pars planitis. Arch. Ophthalmol. 113(10), 1277–1280 (1995).
   PubMedGoogle Scholar
• Mackensen F, Max R, Becker MD. Interferon therapy for ocular disease. Curr. Opin. Ophthalmol. 17(6), 567–573 (2006).
   PubMed Web of Science ®Google Scholar
• Panitch H, Goodin D, Francis G et al.; EVIDENCE (EVidence of Interferon Dose-response: European North American Comparative Efficacy) Study Group and the University of British Columbia MS/MRI Research Group. Benefits of high-dose, high-frequency interferon β-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: final comparative results of the EVIDENCE trial. J. Neurol. Sci. 239(1), 67–74 (2005).
   PubMed Web of Science ®Google Scholar
• PRISMS-4. Long-term efficacy of interferon-β-1a in relapsing MS. Neurology 56(12), 1628–1636 (2001).
   PubMed Web of Science ®Google Scholar
• Galetta SL. The controlled high risk Avonex multiple sclerosis trial (CHAMPS Study). J. Neuroophthalmol. 21(4), 292–295 (2001).
   PubMed Web of Science ®Google Scholar
• Jacobs LD, Beck RW, Simon JH et al. Intramuscular interferon β-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N. Engl. J. Med. 343(13), 898–904 (2000).
   PubMed Web of Science ®Google Scholar
• Constantinescu CS, Lavi E. Anterior uveitis in murine relapsing experimental autoimmune encephalomyelitis (EAE), a mouse model of multiple sclerosis (MS). Curr. Eye Res. 20(1), 71–76 (2000).
   PubMed Web of Science ®Google Scholar
• Kötter I, Zierhut M, Eckstein AK et al. Human recombinant interferon α-2a for the treatment of Behçet’s disease with sight threatening posterior or panuveitis. Br. J. Ophthalmol. 87(4), 423–431 (2003).
   PubMed Web of Science ®Google Scholar
• Becker MD, Heiligenhaus A, Hudde T et al. Interferon as a treatment for uveitis associated with multiple sclerosis. Br. J. Ophthalmol. 89(10), 1254–1257 (2005).
   PubMed Web of Science ®Google Scholar
• Wiendl H, Hohlfeld R. Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials. BioDrugs 16(3), 183–200 (2002).
   PubMed Web of Science ®Google Scholar
• Gordon LK. Uveitis and neurological diseases. Br. J. Ophthalmol. 88(12), 1483–1484 (2004).
   PubMed Web of Science ®Google Scholar
• Mohan N, Edwards ET, Cupps TR et al. Demyelination occurring during anti-TNF-α therapy for inflammatory arthritides. Arthritis Rheum. 44(12), 2862–2869 (2001).
   PubMed Web of Science ®Google Scholar
• Kappos L, Radue EW, O’Connor P et al.; FREEDOMS Study Group. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N. Engl. J. Med. 362(5), 387–401 (2010).
   PubMed Web of Science ®Google Scholar
• Turaka K, Bryan JS. Does fingolimod in multiple sclerosis patients cause macular edema? J. Neurol. 259(2), 386–388 (2012).
   PubMed Web of Science ®Google Scholar
• Saab G, Almony A, Blinder KJ, Schuessler R, Brennan DC. Reversible cystoid macular edema secondary to fingolimod in a renal transplant recipient. Arch. Ophthalmol. 126(1), 140–141 (2008).
   PubMedGoogle Scholar
• Jain N, Bhatti MT. Fingolimod-associated macular edema: incidence, detection, and management. Neurology 78(9), 672–680 (2012).
   PubMed Web of Science ®Google Scholar
• Arnold AC. Evolving management of optic neuritis and multiple sclerosis. Am. J. Ophthalmol. 139(6), 1101–1108 (2005).
   PubMed Web of Science ®Google Scholar
• Balcer LJ. Clinical practice. Optic neuritis. N. Engl. J. Med. 354(12), 1273–1280 (2006).
   PubMed Web of Science ®Google Scholar
• Baier ML, Cutter GR, Rudick RA et al. Low-contrast letter acuity testing captures visual dysfunction in patients with multiple sclerosis. Neurology 64(6), 992–995 (2005).
   PubMed Web of Science ®Google Scholar
• Galetta KM, Graves J, Talman LS et al. Visual pathway axonal loss in benign multiple sclerosis: a longitudinal study. J. Neuroophthalmol. 32(2), 116–123 (2012).
   PubMed Web of Science ®Google Scholar
• Fisher JB, Jacobs DA, Markowitz CE et al. Relation of visual function to retinal nerve fiber layer thickness in multiple sclerosis. Ophthalmology 113(2), 324–332 (2006).
   PubMed Web of Science ®Google Scholar
• Burkholder BM, Osborne B, Loguidice MJ et al. Macular volume determined by optical coherence tomography as a measure of neuronal loss in multiple sclerosis. Arch. Neurol. 66(11), 1366–1372 (2009).
   PubMedGoogle Scholar
• Talman LS, Bisker ER, Sackel DJ et al. Longitudinal study of vision and retinal nerve fiber layer thickness in multiple sclerosis. Ann. Neurol. 67(6), 749–760 (2010).
   PubMed Web of Science ®Google Scholar
• Gelfand JM, Nolan R, Schwartz DM, Graves J, Green AJ. Microcystic macular oedema in multiple sclerosis is associated with disease severity. Brain 135(Pt 6), 1786–1793 (2012).
   PubMed Web of Science ®Google Scholar